These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 39245360)
1. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
2. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers. Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. Mortier L; Villabona L; Lawrence B; Arance A; Butler MO; Beylot-Barry M; Saiag P; Samimi M; Ascierto PA; Spada F; De Pontville M; Maio M; Berrocal A; Espinosa E; Capdevila J; Levin M; Das D; Krepler C; Grebennik D; Chiarion-Sileni V Am J Clin Dermatol; 2024 Nov; 25(6):987-996. PubMed ID: 39377880 [TBL] [Abstract][Full Text] [Related]
4. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658 [TBL] [Abstract][Full Text] [Related]
5. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Mell LK; Torres-Saavedra PA; Wong SJ; Kish JA; Chang SS; Jordan RC; Liu T; Truong MT; Winquist EW; Takiar V; Wise-Draper T; Robbins JR; Rodriguez CP; Awan MJ; Beadle BM; Henson C; Narayan S; Spencer SA; Powell S; Dunlap N; Sacco AG; Hu KS; Park HS; Bauman JE; Harris J; Yom SS; Le QT Lancet Oncol; 2024 Dec; 25(12):1576-1588. PubMed ID: 39551064 [TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615 [TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058 [TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. Peris K; Inocencio TJ; Stratigos AJ; Lewis KD; Eroglu Z; Chang ALS; Ivanescu C; Sekulic A; Fury MG; Chen CI; Quek RGW Cancer Med; 2024 Jul; 13(14):e7360. PubMed ID: 39031963 [TBL] [Abstract][Full Text] [Related]
9. Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Li S; Shi Y; Dong H; Guo H; Xie Y; Sun Z; Zhang X; Kim E; Zhang J; Li Y; Xu C; Kadeerbai H; Lee S; Gorla S; Guo J; Sheng X Cancer Med; 2024 Nov; 13(21):e70368. PubMed ID: 39530574 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Liu SL; Li XY; Yang JH; Wen DX; Guo SS; Liu LT; Li YF; Luo MJ; Xie SY; Liang YJ; Sun XS; Yang ZC; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Lan KQ; Jia GD; Li R; Zhao C; Xu RH; Chen QY; Tang LQ; Mai HQ Lancet Oncol; 2024 Dec; 25(12):1563-1575. PubMed ID: 39522541 [TBL] [Abstract][Full Text] [Related]
11. First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies. Lakhani NJ; Papadopoulos KP; Johnson ML; Park H; Wang D; Yap TA; Dowlati A; Maki RG; Ulahannan S; Lynce F; Kelly K; Williamson S; Malhotra J; Chen S; Gonzalez Ortiz A; Jankovic V; Paccaly A; Masinde S; Mani J; Lowy I; Gullo G; Sims T; Kroog G Clin Cancer Res; 2024 Dec; 30(24):5601-5611. PubMed ID: 39422598 [TBL] [Abstract][Full Text] [Related]
12. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497 [TBL] [Abstract][Full Text] [Related]
13. A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study. Song N; Teng Y; Shi J; Teng Z; Jin B; Qu J; Zhang L; Yu P; Zhao L; Wang J; Li A; Tong L; Jiang S; Liu Y; Yin L; Jiang X; Xu T; Cui J; Qu X; Liu Y Front Immunol; 2024; 15():1481326. PubMed ID: 39676868 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
15. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008 [TBL] [Abstract][Full Text] [Related]
16. Etrolizumab for induction of remission in ulcerative colitis. Rosenfeld G; Parker CE; MacDonald JK; Bressler B Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. Cohen G; Rapoport B; Chan SW; Ruff P; Arance A; Mujika Eizmendi K; Houghton B; Brown MP; Zielinski RM; Muñoz Couselo E; Lyle M; Anderson JR; Jain L; de Alwis D; Lala M; Akala O; Chartash E; Jacobs C PLoS One; 2024; 19(11):e0309778. PubMed ID: 39531423 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Long GV; Carlino MS; McNeil C; Ribas A; Gaudy-Marqueste C; Schachter J; Nyakas M; Kee D; Petrella TM; Blaustein A; Lotem M; Arance AM; Daud AI; Hamid O; Larkin J; Yao L; Singh R; Lal R; Robert C Ann Oncol; 2024 Dec; 35(12):1191-1199. PubMed ID: 39306585 [TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]